. (2012). Hypolipidemic agent Z-guggulsterone: metabolism interplays with induction of carboxylesterase and bile salt export pump.
inserted into the pGL3 basic luciferase vector to prepare reporter CES1A1-7714Luc. This construct was then used as the template to prepare reporters: CES1A1-6981Luc, CES1A1-3582Luc, CES1A1-3432Luc, and CES1A1-2932Luc with the same antisense primer (CES1A1-21XhoIa) but different sense primer ( Table 1 ) . The reporters CES1A1-9622Luc and CES1A1-9332Luc contained additional upstream sequences. To prepare these constructs, human genomic DNA was used as the template with primers CES1A1-4777a and CES1A1-9622Mlus or CES1A1-9333MluIs. The respective fragments were digested with Mlu I and Spe I (an internal site in the fragments). The digested fragments were then ligated to the reporter CES1A1-7714Luc pretreated with the same endonucleases. The CES1A1 guggulsterone element reporter was prepared by inserting the oligonucleotides (5 ′ -CACA ATCTGCAGAGTC-ATCATG AAG-3 ′ ) into the pGL3 promoter vector at the Nhe I and Xho I sites. All constructs were confi rmed by sequencing. The reporter assays were performed as described previously ( 12 ) .
Metabolism of Z-guggulsterone
Metabolism was conducted with recombinant CYPs (1 pmol) and pooled human liver microsomes (20 g ) in a total volume of 100 l ( 18, 19 ) . Preliminary studies were performed to determine conditions supporting the linear rate. Z-Guggulsterone was dissolved in acetonitrile, and the fi nal concentration of the solvent was 0.1%. After 10 min preincubation at 37°C, reactions were initiated by adding the NADPH-regenerating system (NRS) and then were incubated for 40 min. The reactions were terminated by two volumes of ice-cold acetonitrile containing the internal standard spironolactone (10 g/ml), followed by centrifugation. For the inhibition assay, the prereaction mixtures contained a CYP inhibitor at previously reported concentrations ( 20 ) . The metabolism was monitored for the disappearance of Z-guggulsterone by LC-MS/MS (API 3200) ( 19 ) . Detection of the analytes was performed in positive ion mode using the mass transitions of m/z 313.2 → 97.0 for Z-guggulsterone and m/z 416.6 → 341.2 for IS. Injection analysis was performed at a fl ow rate of 200 l/min to obtain optimum source parameters. The assay was linear from 1.04 to 416.27 ng/ml for Z-guggulsterone.
Purifi cation of metabolites
Reactions were set up in a total volume of 1 ml with CYP3A4. The supernatants were separated on a Chromolith SpeedROD column RP-18e (Merck, Germany) by a gradient mobile phase made of 0.1% aqueous formic acid (A) and acetonitrile (B). The mobile phase started with 10% acetonitrile for 2 min, 15% for 5 min, 70% for 3 min, 30% for 4 min, and 10% for 1 min with the fl ow rate of 2 ml/min. The metabolites were detected by a diode array detector at 240 nm. The concentrated metabolites were analyzed by HPLC, and the concentrations were estimated according to the curve generated with Z-guggulsterone at various concentrations. The metabolites were analyzed for the massto-charge ratios by a Q-Star Elite time-of-fl ight mass spectrometer (Applied Biosystems/MDS SCIEX). The LC conditions were the same as described above but with a reduced fl ow rate (0.5 ml/ min). Analytic parameters were as follows: injection volume, 20 l; column temperature, 30°C; DAD range, 210-400 nm with 240 as the detection wavelength; ionization mode, ESI+; scan range, 220-500 amu; and scan rate, 1 scan/s.
Mouse hepatocyte culture and treatment
Primary mouse hepatocytes were isolated from 9-week-old CD-1 mice (male) by a modifi ed two-step collagenase digestion method, essentially as described previously ( 21 ) . Hepatocytes were dispersed from the digested liver in Williams' Medium E (Sigma-Aldrich, St. Louis, MO) without collagenase and washed by low-speed centrifugation (100-150 g , 5 min) three times. Hepatocytes were suspended in Williams' Medium E containing Increased bile acid synthesis has long been explored for the development of drugs with cholesterol-lowering activity. The biliary secretion has a large capacity and is equally effective in eliminating both endogenous and dietary cholesterols. For quite some time, guggul has gained interest worldwide (9) (10) (11) . Originally described in the Indian traditional medicine Ayurveda, guggul has been used for thousands of years to treat conditions such as atherosclerosis ( 9, 12 ) . The hypolipidemic activity has been confi rmed in multiple animal models ( 9 ) . Human clinical trials, however, produced inconsistent results. Some clinical trials reported that guggul lowered plasma cholesterol by 20-30% and triglycerides by 10-20%, with the response rate being as high as 80% ( 9, 13, 14 ) . Other trials, however, did not detect the same level of effectiveness ( 10, 11 ) .
Nonetheless, Z-guggulsterone is recognized as the major active ingredient. Its hypolipidemic activity in mice requires the farnesoid X receptor (FXR) ( 15 ) . This phytosterol is an antagonist of FXR, and such antagonism is assumed to accelerate bile acid synthesis by inducing CYP7A1. To directly test this hypothesis, human primary hepatocytes were treated with Z-guggulsterone, and the expression of CYP7A1 was determined. In addition, the expression of CES1 and BSEP was monitored. Contrary to the general assumption, Z-guggulsterone was an inducer of CES1 and BSEP but not of CYP7A1. In addition, Z-guggulsterone was metabolized, and the metabolites differentially altered CES1 and BSEP induction. Our fi ndings predict that the hypolipidemic activity of Z-guggulsterone depends on two important interplays: CES1 induction versus CYP7A1 activity, and the metabolism of Z-guggulsterone versus the relative inducibility between CES1 and BSEP.
EXPERIMENTAL PROCEDURES

RT-qPCR
Human primary hepatocytes were obtained from the Liver Tissues Procurement and Distribution System (University of Minnesota) or CellzDirect (Pittsboro, NC). The use of the human samples was approved by the Institutional Review Board. Hepatocytes and hepatoma cells (Huh7) were cultured and treated with Z-guggulsterone, chenodeoxycholic acid (CDCA), or both as described previously ( 12 ) . The mRNA levels were determined with TaqMan assays ( 16 ) . The assay identifi cation numbers were CES1, Hs00275607_m1; CYP7A1, Hs00167982_m1; BSEP, Hs00184824_ m1; GAPDH, 4352934E; and RNA polymerase II, Hs00172187_m1. The CES1 probe recognized both CES1A1 and CES1A2, and both enzymes are identical, although encoded by distinct genes ( 17 ) .
Reporter assays
The BSEP guggulsterone element reporter and the FXR expression construct were described elsewhere ( 12 ) . The CES1A1 reporters containing the promoter and its upstream sequence at varying lengths were prepared by inserting the corresponding genomic fragment into the pGL3 basic luciferase vector at the Mlu I and Xho I sites. All genomic fragments were generated by PCR with high-fi delity Platinum Taq DNA polymerase. The primer sequences are listed in Table 1 . Initially, human genomic DNA from the placenta was used as the template for the amplifi cation of the genomic fragment from -7714 to -21 (from the initial translation codon) with primers CES1A1-21XhoIa and 7714MluIs. This fragment was at Univ of Rhode Island, on November 19, 2018 www.jlr.org Downloaded from by increasing bile acid synthesis through inducing CYP7A1. On the other hand, rats fed with guggul herb extract did not show increased expression of CYP7A1 ( 26 ) . Nevertheless, we made an effort to determine whether Z-guggulsterone induces human CYP7A1. Human primary hepatocytes were treated with Z-guggulsterone, and the expression was determined. CDCA, a known suppressor of CYP7A1 ( 27 ) , was included in this study as a negative control. Contrary to the general assumption, Z-guggulsterone caused a 20% decrease of CYP7A1 mRNA ( Fig. 1B ) , although the decrease did not reach statistical signifi cance. As expected, CDCA signifi cantly decreased CYP7A1 mRNA ( Fig. 1B ) . The decrease was partially reversed by Z-guggulsterone 35% percoll. The resulting cell pellet was then suspended in Williams' Medium E containing 10% fetal bovine serum, insulintransferrin-sodium selenite (ITS) supplement, and dexamethasone (100 nM). Cell viability was determined by trypan blue exclusion. Hepatocytes were then plated onto collagen-coated 12-well culture plates. The cells were allowed to attach for 4 h at 37°C in a humidifi ed chamber with 95%/5% air/CO 2 . Culture plates were then gently swirled, and the medium containing unattached cells was aspirated. Fresh medium (free serum) was added to each well, and the cultures were returned to the humidifi ed chamber. Hepatocytes were cultured in the same medium for 48 h, but the medium was changed at 24 h. Thereafter, hepatocytes were cultured in DMEM containing treatment chemicals at appropriate concentrations for 48 h; the treatment medium was replaced once at 24 h. Treated hepatocytes were collected in RIPA buffer for Western blotting . Otherwise, hepatocytes were collected in Tris-HCl (50 mM, pH 7.4), and lysates were prepared by sonication as described previously ( 21 ) . All mice were allowed free access to Purina Rodent Chow 5001 and water, and the use of animals was approved by the Institutional Animal Care and Use Committee.
Electrophoresis-coupled activity determination
Nondenaturing gel electrophoresis for staining esterase activity was conducted as described previously ( 22 ) . Cell lysates (5 or 20 g) was solubilized with 0.2% Lubrol and subjected to electrophoresis with a 3% acrylamide stacking gel and a 7.5% acrylamide separating gel. After electrophoresis, the gels were washed for 1 h in 100 mM potassium phosphate buffer (pH 6.5), followed by incubating in the same buffer containing 1-naphthylacetate (5 mM) and 4-benzolamino-2,5-dimethoxybenzenediazonium chloride hemi (zinc chloride) salt, usually termed Fast Blue RR (0.4 mg/ml). The staining of esterases by this method is based on the formation of a black, insoluble complex between 1-naphthol hydrolyzed from 1-naphthylacetate and Fast Blue RR.
Other analyses
Electrophoretic mobility shift assay (EMSA) was performed as described previously ( 21, 23 ) . Western blotting was detailed elsewhere ( 19, 24 ) . Preparation of CES1 antibody against a peptide was described previously ( 25 ) . The antibody (PC-064) against BSEP (mouse and human) was purchased from Kamiya Biomedical Co. (Seattle, WA), the antibody against human CYP7A1 (ab79847) from Abcam, Inc. (Cambridge, MA), and the antibody against mouse cyp7a1 from Cosmo Bio Co. (Western Carlsbad, CA). Signifi cant differences were determined by one-way ANOVA followed by a Duncan's multiple comparison test ( P < 0.05).
RESULTS
Z-Guggulsterone induces CES1 and BSEP but not CYP7A1
It is generally assumed that Z-guggulsterone exerts hypolipidemic activity based on a feed-back mechanism ( 7 ) Initially, concentration-dependent induction was determined in this line. As shown in Fig. 2A , Z-guggulsterone induced CES1 and BSEP mRNA in a concentrationdependent manner; however, the magnitude of induction varied markedly. Both genes were induced comparably at lower concentrations, but CES1 mRNA was induced to a signifi cantly greater extent at 10 and 20 µM. All data points on CES1 induction signifi cantly differed from each other ( P < 0.05), except those between 0.5 and 1 µM. Likewise, all concentrations caused statistically signifi cant induction of BSEP. However, the magnitudes of the inductions between 0.5 and 1 µM did not differ signifi cantly, and neither did those among 5, 10, and 20 µM. Next, we tested whether actinomycin D, a transcriptional inhibitor, abolishes the induction of both CES1 and BSEP. Huh7 cells were treated with Z-guggulsterone in the presence or absence of actinomycin D. As shown in Fig. 2B , cotreatment ( Fig. 1B ) . The level of CYP7A1 protein showed a pattern of changes similar to the level of CYP7A1 mRNA. In contrast to the suppression of CYP7A1, Z-guggulsterone significantly induced both CES1 and BSEP mRNA with BSEP ( Fig. 1C, D ) . The fold of induction of BSEP was higher than that of CES1 in the primary hepatocytes ( P < 0.05). Cotreatment with CDCA synergistically increased BSEP induction but slightly decreased CES1 induction ( Fig. 1C, D ) . As seen with CYP7A1, the levels of CES1 and BSEP proteins exhibited patterns of changes similar to those of the respective mRNA levels.
Activation of the CES1A1 promoter
We have shown that Z-guggulsterone induces BSEP through transactivation ( 12 ) . Next, we tested whether transactivation is also involved in CES1 induction. Huh7 cells (a human hepatic line) were used for this study. contained three copies. Nevertheless, EMSA with nuclear extract from Z-guggulsterone treated Huh7 cells detected a shifted band with the CES1A1 element. This binding was competed effectively by the corresponding nonlabeled element ( Fig. 3B ) . In contrast, the mutant element (5 ′ -CA-CAAT G T A C T GAG GA ATCATGAAG-3) had no competitive effect ( Fig. 3B ) .
Metabolism by CYP3A4
As described in Figs. 1 and 2 , BSEP mRNA was induced higher in primary hepatocytes, whereas CES1 mRNA was induced comparably or higher in Huh7 cells, depending on the concentrations. One explanation is that primary hepatocytes express higher basal levels of CES1 and, thus, the inducibility is lower. Another explanation is that primary hepatocytes, but not Huh7 ( 28 ), effectively metabolize Z-guggulsterone. To test whether Z-guggulsterone actually undergoes metabolism, incubations were performed with pooled human liver microsomes in the presence or absence of the NADPH-regenerating system. This system is required for reactions catalyzed by CYPs and fl avin monooxygenases ( 28 ) . As shown in Fig. 4A , the reaction incubated without NRS, like zero-minute incubation, yielded a peak with a retention time of 7.92 min (i.e., Z-guggulsterone). This peak, with actinomycin D completely abolished the induction of both CES1 and BSEP, suggesting that Z-guggulsterone induces CES1, like BSEP ( 12 ), through transactivation. We next tested whether Z-guggulsterone stimulates the promoter of CES1A1, the predominant form of the CES1 genes ( 17 ) . As shown in Fig. 2C , all reporters were activated by Z-guggulsterone, except reporters CES1A1-3432luc and CES1A1-2932Luc. The maximum activation was 6-fold and occurred with the reporter CES1A1-3582-Luc ( Fig. 2C ) . CES1A1-3432luc, the immediate reporter shorter than CES1A1-3582Luc, no longer responded to Z-guggulsterone, suggesting that this 150-bp genomic fragment (-3582 to -3432) supports the transactivation.
To precisely specify the sequence for the transactivation, element reporters (20-25 bases each) were prepared to span the entire region with overlapping sequence. Among the element reporters, only one reporter, designated CES1A1Gugg-Luc, responded to Z-guggulsterone ( Fig. 3A ) . This and the BSEPGugg-Luc reporter were tested for the activation as a function of Z-guggulsterone. As shown in Fig. 3A , the CES1A1 element reporter was activated much higher, except at the 20 µM data point ( Fig. 3A ) . Note that the CES1 reporter contained only a single copy of the element, whereas the BSEP reporter ( Fig. 4B ) . Ketoconazole caused complete inhibition, whereas the CYP1A2 inhibitor furafylline caused no inhibition. Isoform-specifi c substrates were used to confi rm the activity of each inhibitor.
The inhibition study demonstrated that multiple CYPs metabolized Z-guggulsterone, with the CYP3A4 being the most active. To directly test this possibility, recombinant CYPs were tested for metabolism. Consistent with the inhibition study, CYP3A4 had the highest activity ( Fig. 4C ) . Moderate metabolism was detected with CYP1A2, 2A6, and 2B6; slight metabolism was detected with CYP2C19 and 2D6; and no metabolism was detected with CYP2C8, 2C9, and 2E1 ( Fig. 4C ) . Interestingly, CYP1A2 was the second most active toward Z-guggulsterone, although the corresponding inhibitor showed no activity ( Fig. 4B ) . Specifi c substrates for each CYP were included to verify the catalytic activity of each recombinant CYP.
Purifi cation of major metabolites
To determine whether the metabolism alters the induction potency, we purifi ed several major metabolites. Initially, we performed a time-course study to determine the kinetics of the metabolism by recombinant CYP3A4. As shown in Fig. 5A , the parent compound was disappeared by ‫ف‬ 70% within 30 min of incubation. Prolonged incubation further increased the metabolism. The metabolite profi le generated by CYP3A4 was very similar to that generated by liver microsomes ( Figs. 4A and 5A ), confi rming that this CYP is the primary enzyme for the metabolism. Interestingly, the 30 min incubation produced similar amounts of M1 and M4; however, prolonged incubation produced more M1 than M4 ( Fig. 5A ) . To this end, we purifi ed M1, M2, M3, and M4 to homogeneity. As shown in Fig. 5B -E , all purifi ed metabolites produced a single peak with a predicated retention time. Mass spectrometry revealed that M1 was at m/z 345 and the other three metabolites at 329. Z-Guggulsterone had a mass-to-charge ratio of 313. Therefore, M1 represented an addition of two hydroxyl groups, whereas the others resulted from an addition of a single hydroxyl group.
Induction potency of major metabolites
To determine whether the metabolites and Z-guggulsterone differ in the induction potency, RT-qPCR and reporter assays were performed. The concentrations of the metabolites were estimated based on the area under the curve. This study included all major metabolites except M2, which was not suffi cient to generate the standardized concentration (2 µM). Compared with Z-guggulsterone, all metabolites caused signifi cant increases in the level of BSEP mRNA ( Fig. 6A ) , with M3 causing the highest increase (> 3-fold). In contrast, the magnitude of changes in CES1 mRNA was much less. Compared with Z-guggulsterone, M1 caused a 47% increase, M3 caused a 12% decrease, and M4 caused a 22% increase in CES1 induction ( Fig. 6A ) . All metabolites tested showed signifi cantly higher induction of BSEP than CES1 mRNA ( Fig. 6A ). however, disappeared by ‫ف‬ 90% when the incubation was performed in the presence of NRS ( Fig. 4A ) . At the same time, several metabolite peaks appeared with a retention time of 4.69 min (M1), 5.60 (M2), 5.92 (M3), and 6.56 (M4), respectively. M3 was the most abundant ( Fig. 4A ) .
The majority of oxidations are catalyzed by the CYP system ( 28 ). We next tested whether one or more CYPs metabolize Z-guggulsterone. Incubations were conducted with pooled microsomes but in the presence of a CYP inhibitor. A total of nine inhibitors were used, including furafylline (CYP1A2), pilocarpine (CYP2A6), thio-tepa (CYP2B6), quercetin (CYP2C8), sulfaphenazole (CYP2C9), ticlopidine (CYP2C19), quinidine (CYP2D6), chlormethiazole (CYP2E1), and ketoconazole (CYP3A4/5). With the exceptions of furafylline whereas the maximal change in the activation by M1 was ‫ف‬ 2-fold ( Fig. 6B ) . To further determine whether CYP3A4-based metabolism of Z-guggulsterone differentially alters BSEP and CES1 induction, Huh7 cells were transfected with CYP3A4 or the vector, treated with Z-guggulsterone (5 µM), and then analyzed for the induction of CES1 and BSEP mRNA. As shown in Fig. 6C , cotransfection of CYP3A4, compared with the vector, signifi cantly increased BSEP but not CES1 induction.
Effect of Z-guggulsterone on the expression of mouse bsep, cyp7a1, and carboxylesterases (ces)
To determine whether Z-guggulsterone modulates the expression of the corresponding mouse genes, mouse primary hepatocytes were treated with Z-guggulsterone, CDCA, or both. As shown in Fig. 7A , Z-guggulsterone signifi cantly induced bsep but not cyp7a1, and inductions were not affected by CDCA cotreatment. These responses were consistent with the responses on the expression of BSEP and CYP7A1 in rats fed with guggul extract ( 26 ) .
We next tested the activation of CES1 and BSEP element reporters by various metabolites. The results are summarized in Fig. 6B . The changes in element reporter activation, compared with those in the induction of CES1 and BSEP mRNA, had several important differences. First, all metabolites showed increases in the activation of the element reporters, which was not true in mRNA induction ( Fig. 6A, B ) . For example, metabolite M3 actually caused a slight decrease in the induction of CES1 mRNA. Second, between CES1A1 and BSEP, metabolites generally caused less difference in the activation of the element reporters than in induction of the mRNA ( Fig. 6A, B ) . For example, metabolite M1 caused much higher increases in the induction of BSEP mRNA than CES1 mRNA, whereas this metabolite caused similar increases in the activation of both element reporters ( Fig. 6A, B ) . And third, the overall changes in the CES1 element reporter activation were greater than those in the induction of CES1 mRNA. For example, compared with Z-guggulsterone, the maximal change in the induction by M1 was 47% increase ( Fig. 6A ) , Z-guggulsterone, like the induction of BSEP, was achieved by transactivation ( Fig. 2 ) . The transactivation depended on a particular genomic sequence designated as the CES1A1 guggulsterone element ( Fig. 3A ) . Coincidently, both CES1A1 and BSEP guggulsterone response elements contain an a ntioxidant r esponse e lement (ARE) and an AP-1 site ( Fig. 8A ) . However, the CES1A1 ARE is orientated in an opposite direction to that of BSEP ( Fig. 8A ) . Also, the CES1A1 AP-1 site (AGAGTCA) slightly differs from that of BSEP ( T GA A TCA) ( Fig. 8A ). More importantly, these two elements differentially responded to Z-guggulsterone and its metabolites, particularly metabolite M3 ( Fig. 6B ) . Compared with Z-guggulsterone, M3 increased the activation of the BSEP reporter from 2.6-to 7.3-fold, whereas the increase was much less in the activation of the CES1A1 reporter from 3.2-to 4.3-fold ( Fig. 6B ) . On the other hand, similar responses were detected between the reporter activation and mRNA induction of BSEP ( Fig. 6A, B ) , whereas the reporter activation of CES1 was much higher than the corresponding mRNA induction ( Fig. 6A, B ) . One explanation is that the BSEP element provides the primary mechanism for BSEP induction by Z-guggulsterone, whereas the CES1A1 element represents one of the mechanisms for CES1 induction.
Clearly, the metabolism of Z-guggulsterone is determined largely by CYP3A4. The metabolite profi le generated As expected, CDCA, a weak activator of mouse fxr ( 26 ) , caused little changes in the expression of bsep or cyp7a1 ( Fig. 7A ) . Next we tested whether these treatments alter the expression of mouse carboxylesterases. In terms of the number of carboxylesterase genes, mice have almost three times as many as humans ( 29 ) . The relative level of carboxylesterases can be indirectly determined by nondenaturing electrophoresis, followed by staining for hydrolytic activity with 1-naphythalacetate ( 22 ) . This standard substrate can be hydrolyzed by many carboxylesterases. As shown in Fig. 7B (left) , both CDCA and Z-guggulsterone markedly induced several major mouse carboxylesterases, such as ces2e and ces2c, but not many others, such as ces1d (the mouse counterpart of human CES1). The identity of some of the electrophoretically distinct mouse carboxylesterases remains to be established. As expected, Z-guggulsterone signifi cantly increased hydrolysis by CES1 but much less so by CES2 ( Fig. 7B , right) . Cotreatment with CDCA slightly decreased the increased hydrolysis of CES1 by Z-guggulsterone.
DISCUSSION
This study has shown that Z-guggulsterone signifi cantly induced CES1 and BSEP. The induction of CES1 by contributes less, if any, to the hepatic metabolism of Zguggulsterone. Another interesting observation was that CYP3A4 produced various metabolites ( Fig. 5A ) . Most of them resulted from addition of a single hydroxyl group ( Fig. 5C-E ) . In contrast, the formation of M1 resulted from addition of two hydroxyl groups ( Fig. 5B ) . Prolonged incubation increased the production of M1 but proportionally decreased M4 ( Fig. 5A ) , suggesting that M4 is a substrate of CYP3A4 to produce M1 ( Fig. 5A ) .
Although the purifi ed metabolites generally increased the induction of both CES1 and BSEP, the magnitude was much greater on BSEP ( Fig. 6 ) . Secretion of bile acids represents net elimination of cholesterol ( 8 ); therefore, induction of BSEP favors lowering cholesterol. In contrast, induction of CES1 may favor the elimination or recycling of cholesterol, probably depending on the level of CYP7A1 ( Fig. 8B ) . Given that the action of CES1 leads to increased free cholesterol, high levels of CYP7A1 in individuals would facilitate the conversion of cholesterol into bile acids, whereas low levels of CYP7A1 in others would favor the pathway of VLDL assembling (double-lined arrow in Fig. 8B ). Therefore, individuals with a high level of BSEP induction relative to CES1 induction (probably with high capacity of metabolizing guggulsterones) would benefi t more in lowering cholesterol. Accordingly, the purifi ed by human microsomes was similar to that by CYP3A4 ( Figs. 4A and 5A ). On the other hand, there were several interesting observations, particularly regarding the metabolism by CYP1A2 ( Fig. 4B, C ) . Furafylline, an inhibitor of CYP1A2, showed little inhibition of Z-guggulsterone metabolism by liver microsomes ( Fig. 4B ), yet recombinant CYP1A2 signifi cantly metabolized this phytosterol ( Fig. 4C ) . One explanation is that Z-guggulsterone is a substrate of both CYP3A4 and CYP1A2, but CYP3A4 has higher affi nity and more effi ciently metabolizes the phytosterol. In addition, CYP3A4 is two to three times more abundant than CYP1A2 in the liver ( 28 ) . Therefore, CYP1A2 normally ( Fig. 1B ) ; and interestingly, the suppression was partially reversed by Z-guggulsterone. These fi ndings suggest that Z-guggulsterone downregulates CYP7A1 through both PXR and FXR, with FXR requiring higher presence of bile acids. In addition, Z-guggulsterone and CDCA synergistically induced BSEP ( Fig. 1D ) , further weakening the feedback mechanism, although it remains to be ascertained whether and to which extent the feed-back mechanism contributes to the hypolipidemic activity of Z-guggulsterone.
In summary, our study presents two interplays that likely determine the overall hypolipidemic activity of guggul ( Fig. 7 ) . The fi rst interplay occurs between CES1 induction and CYP7A1 activity. CES1 induction within the capacity of CYP7A1 favors the synthesis of bile acids and elimination of cholesterol. Excessive induction of CES1 beyond the capacity of CYP7A1 likely increases the engagement of this enzyme in the hydrolysis/reesterifi cation cycle, favoring VLDL assembly. The second interplay occurs between the metabolism of guggulsterones and the induction of BSEP/CES1. Increased metabolism enhances BSEP induction and probably decreases the induction of CES1. It is, therefore, expected that individuals with a higher capacity of metabolizing guggulsterones (probably lower dosing) will show lower induction of CES1 and have better hypolipidemic outcomes. metabolites likely deliver more favorable hypolipidemic profi les than Z-guggulsterone. The dosage, on the other hand, is another factor that may infl uence the hypolipidemic effi cacy. The standard dosage (3 × 1,000 mg guggul extract/daily) in a random trial increased the VLDLcholesterol by 6.4%, whereas the high dosage (3 × 2,000 mg/daily) increased it by 9.8%, pointing to the excessive induction of CES1 ( 14 ) . We have shown that CYP3A4 effi ciently metabolized Z-guggulsterone ( Figs. 4B, C and 5A ) and that cotransfection of CYP3A4 favors the induction of BSEP but not CES1 ( Fig. 6C ) . A previous study identifi ed Z-guggulsterone as a potent activator of the pregnane X receptor (PXR) ( 30 ), a nuclear receptor supporting CYP3A4 induction. Therefore, dosages even lower than the standard dosage likely produce suffi cient metabolites with high potency on BSEP induction and, thus, produce better plasma lipid profi les. Note that Z-guggulsterone also induced several mouse carboxylesterases ( Fig. 7B ,  left) ; however, it remains to be determined whether these carboxylesterases favor lipid retention or elimination.
The metabolism-based alteration of the biological activity may contribute signifi cantly to the observed individual variations in guggul hypolipidemic effi cacy. In Indian populations, the positive rate in lowering LDL cholesterol is 60-80% ( 13, 14 ) , whereas the rate in American populations is only 18% ( 10 ) . The precise mechanism on the large variation in the positive rates remains to be determined. In addition to a much lower dosing regimen in the India trials, differences in metabolism likely contribute to the variations ( 31 ) . Unfortunately, none of the clinical trials reported the blood concentrations of guggulsterones ( 10, 14 ) . We and other investigators have shown that Zguggulsterone is a substrate (this study) and an inducer of CYP3A4 ( 27 ) . Therefore, the involvement of CYP3A4 in the metabolism presents a major variable for guggul therapy due to its variants, diverse substrates, and altered expression by pathological conditions and coadministered drugs ( 21, 32, 33 ) . People normally consume guggul supplement but not purifi ed guggulsterones. As a result, other components in the extracts ( 34 ) may modulate the hypolipidemic activity of guggulsterones by acting on the genes relevant to the hypolipidemic action or the metabolism of guggulsterones.
Z-Guggulsterone, an FXR antagonist, is assumed to downregulate CYP7A1 through the bile acid-FXR feedback mechanism. It was surprising that this phytosterol alone downregulated CYP7A1 by ‫ف‬ 20% ( Fig. 1B ) . It has been reported that primary hepatocytes produce CDCA, the most potent bile acid in triggering the feedback mechanism ( 27 ) , at the level ( ‫ف‬ 1 µM) in medium comparable to that in normal human plasma ( 35, 36 ) , suggesting that the feedback mechanism is operational in primary hepatocytes. The lack of the induction of CYP7A1 by Z-guggulsterone points to a pathway that overrides the feedback mechanism. While Z-guggulsterone has been shown to modulate the activities of many nuclear receptors, activation of PXR led to the repression of the CYP7A1 promoter ( 36, 37 ) . On the other hand, treatment with CDCA (10 µM) caused greater CYP7A1 suppression than Z-guggulsterone
